Full text not available from this repository.

Abstract

Background: Non-alcoholic fatty liver disease (NAFLD) patients represent a vulnerable population that may be susceptible to more severe COVID-19. Moreover, not only the underlying NAFLD may influence the progression of COVID-19, but the COVID-19 may affect the clinical course of NAFLD as well. However, comprehensive evidence on clinical outcomes in patients with NAFLD is not well characterized.Objectives: To systematically review and meta-analysis the evidence on clinical outcomes in NAFLD patients with COVID-19.Methods: MEDLINE, EMBASE, and Cochrane Central were searched from inception through November 2020. Epidemiological studies assessing the clinical outcomes in COVID-19 patients with NAFLD were included. Newcastle-Ottawa Scale (NOS) was used to assess study quality. Generic inverse variance method using RevMan was used to determine the pooled estimates using the random-effects model.Results: Fourteen studies consisting of 1851 NAFLD patients, were included. Significant heterogeneity was observed among the studies, and studies were of moderate to high quality [mean, (range):8 (6, 8)]. For NAFLD patients, the adjusted odds ratio (aOR) for the severe COVID-19 was 2.60 (95%CI:2.24-3.02; p Conclusions: An increased risk of severe COVID-19 infection and admission to ICU due to COVID-19 with no difference in mortality was observed between NAFLD and non-NAFLD patients. Future studies should include the mortality outcome to conclusively elucidate the impact of NAFLD in patients with COVID-19.

Item Type:	Article
Authors/Creators:	Singh, A and Hussain, S and Antony, B
Keywords:	NAFLD,COVID-19, mortality, severity, systematic review
Journal or Publication Title:	Diabetes & Metabolic Syndrome
Publisher:	Elsevier Ltd.
ISSN:	1871-4021
DOI / ID Number:	10.1016/j.dsx.2021.03.019
Copyright Information:	Copyright 2021 Diabetes India
Related URLs:	Google Scholar: Antony, B
Item Statistics:	View statistics for this item

Actions (login required)

Item Control Page